loader image
Saturday, October 18, 2025
71.8 F
McAllen
- Advertisement -

Promising Drug to Treat Gastrointestinal Cancers

Translate to Spanish or other 102 languages!

The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function. Image for illustration purposes.
The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function. Image for illustration purposes.

Mega Doctor News

- Advertisement -

By Mayo Clinic 

Newswise — PHOENIX  Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.

Tanios Bekaii-Saab, M.D., an investigator from Mayo Clinic Cancer Center, has conducted research on adagrasib that has demonstrated promising clinical activity in patients with gastrointestinal cancers that harbor KRAS G12C mutations, including pancreatic cancer, biliary tract cancer and other upper gastrointestinal cancers. Dr. Bekaii-Saab recently presented the results of this research as part of the KRYSTAL-1 clinical trial (NCT03785249) at the American Society of Clinic Oncology’s Genitourinary Cancers Symposium.

- Advertisement -

“The prognosis for patients whose cancer harbors a KRAS gene mutation is particularly poor, and researchers’ attempts to target KRAS G12C, which represents less than 5% of all KRAS mutations in this group of cancers, have failed until only recently,” says Dr. Bekaii-Saab.

“Our data recently presented at ASCO GI (the symposium) showed that adagrasib not only inhibits cancers with a KRASG12C mutation effectively, but also showed promising clinical activity in patients with gastrointestinal cancers.”

Dr. Bekaii-Saab says the gastrointestinal cancers for all patients treated in this phase 2 cohort were controlled, with close to half showing evidence of significant and durable tumor shrinkage.

“These results were very impressive in treating a group of diseases that tend to have a particularly poor outcome,” says Dr. Bekaii-Saab. “We were pleasantly surprised by these findings, given that our previous experience with another similar agent was disappointing in this particular group of patients.”

- Advertisement -

He says research with adagrasib is ongoing. If these trends continue, the drug may eventually prove to be a new option for patients with pancreatic, biliary tract and other gastrointestinal cancers.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

The Human Bean’s “Coffee for a Cure” to Benefit The Renaissance Cancer Foundation, Oct. 17th

The Human Bean located at 1124 E. Nolana in McAllen is inviting coffee-lovers to "drink pink" on October 17 for their annual “Coffee for a Cure” breast cancer giveback event. All food and beverage proceeds on that day will benefit the Renaissance Cancer Foundation, marking The Human Bean’s largest fundraiser of the year.

2025 DHR Health Fashion Show & Gala Honoring Heroic Patients

The Edinburg Conference Center at Renaissance was filled with emotion, gratitude, and hope on Wednesday, October 15, 2025, as DHR Health hosted its 2025 Fashion Show & Gala Honoring Heroic Patients. The annual event celebrated breast cancer survivors and highlighted the importance of breast reconstruction awareness, education, and innovation in women’s health care.

The Harmful Effects of Alcohol on the Brain

Millions of people drink alcohol, and while many may know the harm it can cause to their liver, some may be surprised to know it can be just as damaging to the brain.

STC’s Chapa Turns Curiosity into Purpose

At just 19-years-old, STC Psychological Science student Gianna Chapa has already built a foundation for her future that reflects both determination and heart.
- Advertisement -
×